---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Expected outcomes of therapy"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Expected outcomes of therapy. Topics: Durability of a one-time gene therapy: ICER modeling assumption and clinical expert input, Link between cUHDRS and long-term outcomes: ICER rationale for modeling Total Functional Capacity, Procedure-related outcomes in the ICER assessment, Placebo and practice effects when trial data are compared with natural history, and 12 further topics. 17 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
- Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
- Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
- Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/); [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [FDA externally controlled trials draft guidance (2023)](https://www.fda.gov/media/164960/download); [Jahanshahi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/); [Hernandez (2025)](https://en.hdbuzz.net/483-additional-clarity-what-we-know-4-weeks-after-the-uniqure-news/); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)

<a id="topic-2.2.2.7-2"></a>

### Durability of a one-time gene therapy: ICER modeling assumption and clinical expert input

> “Clinical experts noted that because neurons do not divide, the treatment effect may persist and not dilute over time.”
> “However, substantial uncertainty remains around long-term efficacy”
> “The treatment effect will be assumed to remain constant over the lifetime horizon.”
> “As AMT-130 is a one-time gene therapy, discontinuation will not be modeled.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.7-3"></a>

### Link between cUHDRS and long-term outcomes: ICER rationale for modeling Total Functional Capacity

> “Although TFC may not fully capture cognitive and neuropsychiatric symptoms related to HD, there is currently no established mapping between measures such as the cUHDRS to costs, utilities or mortality.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.7-4"></a>

### Procedure-related outcomes in the ICER assessment

> “The outcomes of interest are described in the list below.”
> “Adverse events including:”
> “Procedure-related adverse events (e.g., headache, complications, pain)”
> “Post lumbar puncture syndrome”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-2.2.2.7-5"></a>

### Placebo and practice effects when trial data are compared with natural history

> “Of interest, the cognitive scores (SDMT, SWR) exhibited an even stronger placebo response that was sustained after the dosing period of the trial ended.”
> “It is important to note that these effects also significantly influence the cUHDRS score, given that it is derived from a linear relationship between TFC, TMS, SDMT score, and SWR score.”
> “However, our analysis also emphasizes the potential for misleading interpretations when comparing trial data with retrospective natural history studies, particularly in distinguishing placebo response from drug effect.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.2.7-6"></a>

### Interpretation of externally controlled comparisons: FDA draft guidance

> “Scenarios that would not be suitable for externally controlled trials include when the natural history of the disease of interest is not understood sufficiently or when the disease course is considered well-understood but is variable.”
> “Changes over time in the understanding of the natural history of a disease can also introduce bias in an externally controlled trial.”

Source: [FDA externally controlled trials draft guidance (2023)](https://www.fda.gov/media/164960/download)

<a id="topic-2.2.2.7-7"></a>

### External controls in FDA approvals, 2000 to 2019: sources and endpoints

> “Forty-five approvals were identified where FDA accepted external control data in their benefit/risk assessment”
> “Retrospective natural history data, including retrospective reviews of patient records, was the most common source of external control (44%).”
> “The vast majority (87%) of cases identified utilized an objective measure as a primary endpoint.”
> “For the few cases where the endpoint was subjective, the benefit was so large it was unlikely to be due to chance alone.”

Source: [Jahanshahi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8332598/)

<a id="topic-2.2.2.7-8"></a>

### Independent commentary on the natural history comparator and durability of AMT-130

> “The people in this trial could be going to the clinic more frequently than those in the Enroll-HD comparator group, causing a medical response bias that improves their symptoms.”
> “So for a Phase 1/2 trial like this one for AMT-130, a natural history comparator can give us an idea if a drug is meeting certain metrics, but isn’t robust enough to conclusively tell us if a gene therapy is effective.”
> “Even with the permanence of this treatment, how durable will it be? Will it wear off over time?”
> “Key questions remain: durability of benefit, variability of response, affordability, and future accessibility.”

Source: [Hernandez (2025)](https://en.hdbuzz.net/483-additional-clarity-what-we-know-4-weeks-after-the-uniqure-news/)

<a id="topic-2.2.2.7-9"></a>

### Natural history-based evidence and assumed duration of benefit: Prilenia comment to ICER

> “Prilenia thanks ICER for the opportunity to submit input at the scoping stage of this assessment.”
> “AMT-130’s evidence relies on comparing treated patients to a propensity-matched group from Enroll-HD although the original design includes a 1-year placebo arm.”
> “While Enroll-HD is a strong registry, this type of natural-history comparison has built-in limits: important patient differences that can’t be matched, such as caudate and putamen size (a key prognostic inclusion criterion absent from Enroll-HD), bias from who chooses to enter a surgical trial versus a registry, different visit schedules, possible behavior changes after surgery, and very small numbers of treated patients at longer follow-up.”
> “For AMT-130, assumptions about how long the benefit lasts will heavily shape the results.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.7-10"></a>

### Composite clinical progression measure in early Huntington's disease

> “Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-2.2.2.7-11"></a>

### Clinically meaningful change on the cUHDRS

> “Analyses anchored against CGI-S and IS support that a decline on the cUHDRS of 1.2 points is clinically meaningful, and that the cUHDRS tracks function decline.”
> “Based on these values, a decline of 1.2 points is recommended as an estimate of meaningful within-patient decline for use in a responder analysis endpoint in clinical trials in patients with early manifest HD.”

Source: [Trundell et al. (2018)](https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/ehdn-2018/EHDN_2018_HD_cUHDRS_Poster_Trundell_non_restricted.pdf)

<a id="topic-2.2.2.7-12"></a>

### Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback

> “The FDA continued to support its prior agreement that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-2.2.2.7-13"></a>

### Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD

> “The primary endpoint will be the change from baseline up to month 36 in the cUHDRS.”

Source: [PTC Therapeutics (2026)](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-reports-positive-topline-results-month-24)

<a id="topic-2.2.2.7-14"></a>

### Time to functional decline as an endpoint

> “A delay of 9 months or more in the transition to Stage 3 for an enriched sample yields feasible sample size estimates, demonstrating that this approach can aid in planning future trials.”

Source: [Mills et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39101272/)

<a id="topic-2.2.2.7-15"></a>

### Cognitive endpoints and regulatory meaningfulness

> “Thus, improvements or declines in performance on the SDMT alone are not sufficient for demonstrating meaningful effects that could lead to regulatory approval of a treatment.”

Source: [Roiboit and Stout (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12839483/)

<a id="topic-2.2.2.7-16"></a>

### Aims of disease-modifying treatment and modeled long-term outcomes

> “Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.”
> “Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.”

Source: [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)

<a id="topic-2.2.2.7-17"></a>

### Expected outcomes of symptomatic chorea treatment

> “By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.”

Source: [Furr Stimming et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42446188/)

Additional sources: [Trundell et al. (2019)](https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P1.8-043)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
